Allon Therapeutics
Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on developing the first drugs that impact the progression of neurodegenerative diseases. Therapies available today treat only symptoms and have no effect on the course of the diseases.
news

> August 11, 2010
 Allon Therapeutics releases second quarter operating results

> August 9, 2010
 Allon’s CEO presenting at Canaccord Genuity Growth Conference

> July 19, 2010
 Allon receives New Economy 2010 Pharmaceutical & Healthcare Award for drug development innovation

> The New Economy Award
Intreview with CEO - Gordon McCauley
video

THE TANGLES PATHWAY TO ALZHEIMERS

Allon’s human clinical trials and animal studies show that davunetide reduces the classic Alzheimer’s “tangles” pathology and also increases memory function.